Overview of green tea interaction with cardiovascular drugs

Current Pharmaceutical Design

Volumn 21, Issue 9, 2015, Pages 1213-1219

  Werba, José P ^a   Misaka, Shingen ^b   Giroli, Monica G ^a   Yamada, Shizuo ^c   Cavalca, Viviana ^a,d   Kawabe, Keisuke ^c   Squellerio, Isabella ^a   Laguzzi, Federica ^a   Onoue, Satomi ^c   Veglia, Fabrizio ^a   Myasoedova, Veronika ^a   Takeuchi, Kazuhiko ^e   Adachi, Eisuke ^e   Inui, Naoki ^e   Tremoli, Elena ^a,d   Watanabe, Hiroshi ^e  

^a CENTRO CARDIOLOGICO MONZINO   (Italy)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^c UNIVERSITY OF SHIZUOKA   (Japan)

^d UNIVERSITY OF MILAN   (Italy)

^e HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cardiovascular drugs; Catechins; Dietary drug interaction; Green tea; Herb drug interaction; Nadolol; Simvastatin; Warfarin

Indexed keywords

CARDIOVASCULAR AGENT; CATECHIN; NADOLOL; SIMVASTATIN; WARFARIN; TEA;

ARTICLE; CARDIOVASCULAR EFFECT; CHEMICAL COMPOSITION; DRUG BIOAVAILABILITY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; HUMAN; NONHUMAN; PRIORITY JOURNAL; TEA; ADVERSE EFFECTS; HERB DRUG INTERACTION;

CARDIOVASCULAR AGENTS; HERB-DRUG INTERACTIONS; HUMANS; NADOLOL; SIMVASTATIN; TEA; WARFARIN;

EID: 84925878509     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666141013135045     Document Type: Article

References (51)

1. Hunter DJ, Reddy KS. Noncommunicable diseases. N Engl J Med 2013; 369: 1336-43.
2. Harris RZ, Jang GR, Tsunoda S. Dietary effects on drug metabolism and transport. Clin Pharmacokinet 2003; 42: 1071-88.
3. Izzo AA, Di Carlo G, Borrelli F, Ernst E. Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction. Int J Cardiol 2005; 98: 1-14.
4. Colalto C. Herbal interactions on absorption of drugs: Mechanisms of action and clinical risk assessment. Pharmacol Res 2010; 62: 207-27.
5. Izzo AA. Interactions between herbs and conventional drugs: overview of the clinical data. Med Princ Pract 2012; 21: 404-28.
6. Tachjian A, Maria V, Jahangir A. Use of herbal products and potential interactions in patients with cardiovascular diseases. J Am Coll Cardiol 2010; 55 : 515-25.
7. Reto M, Figueira ME, Filipe HM, Almeida CM. Chemical composition of green tea (Camellia sinensis) infusions commercialized in Portugal. Plant Foods Hum Nutr 2007; 62: 139-44.
8. Seeram NP, Henning SM, Niu Y, Lee R, Scheuller HS, Heber D. Catechin and caffeine content of green tea dietary supplements and correlation with antioxidant capacity. J Agric Food Chem 2006; 54: 1599-603.
9. Schonthal AH. Adverse effects of concentrated green tea extracts. Mol Nutr Food Res 2011; 55: 874-85.
10. Lin YS, Tsai YJ, Tsay JS, Lin JK. Factors affecting the levels of tea polyphenols and caffeine in tea leaves. J Agric Food Chem 2003; 51: 1864-73.
11. Cheong W, Park M, Kang G, Ko J, YJ S. Determination of catechin compounds in korean green tea Infusions under various extraction conditions by high performance liquid chromatography. Bull Korean Chem Soc 2005; 26: 747-54.
12. Cheng TO. Green tea may inhibit warfarin. Int J Cardiol 2007; 115: 236.
13. Heck AM, DeWitt BA, Lukes AL. Potential interactions between alternative therapies and warfarin. Am J Health Syst Pharm 2000; 57: 1221-7.
14. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165: 1095-106.
15. Nutescu EA, Shapiro NL, Ibrahim S, West P. Warfarin and its interactions with foods, herbs and other dietary supplements. Expert Opin Drug Saf 2006; 5: 433-51.
16. Wittkowsky AK. Dietary supplements, herbs and oral anticoagulants: the nature of the evidence. J Thromb Thrombolysis 2008; 25: 72-7.
17. Taylor JR, Wilt VM. Probable antagonism of warfarin by green tea. Ann Pharmacother 1999; 33: 426-8.
18. Takahashi H, Kashima T, Nomizo Y, et al. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin Pharmacol Ther 1998; 63: 519-28.
19. Yu HC, Chan TY, Critchley JA, Woo KS. Factors determining the maintenance dose of warfarin in Chinese patients. QJM 1996; 89: 127-35.
20. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285-93.
21. Wadelius M, Chen LY, Downes K, et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 2005; 5: 262-70.
22. Booth S, Sadowski J, Weihrauch J, Ferland G. Vitamin K1 (Phylloquinone) content of foods: a provisional table. J Food Comp Anal 1993; 6: 109-20.
23. Booth SL, Madabushi HT, Davidson KW, Sadowski JA. Tea and coffee brews are not dietary sources of vitamin K-1 (phylloquinone). J Am Diet Assoc 1995; 95: 82-3.
24. Werba JP, Giroli M, Cavalca V, Nava MC, Tremoli E, Dal Bo L. The effect of green tea on simvastatin tolerability. Ann Intern Med 2008; 149: 286-7.
25. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004; 109(23 Suppl 1): III50-7.
26. Feng WY. Metabolism of green tea catechins: an overview. Curr Drug Metab 2006; 7: 755-809.
27. Misaka S, Kawabe K, Onoue S, et al. Effects of green tea catechins on cytochrome P450 2B6, 2C8, 2C19, 2D6 and 3A activities in human liver and intestinal microsomes. Drug Metab Pharmacokinet 2012; 28:244-9.
28. Nishikawa M, Ariyoshi N, Kotani A, et al. Effects of continuous ingestion of green tea or grape seed extracts on the pharmacokinetics of midazolam. Drug Metab Pharmacokinet 2004; 19: 280-9.
29. Chow HH, Hakim IA, Vining DR, et al. Effects of repeated green tea catechin administration on human cytochrome P450 activity. Cancer Epidemiol Biomarkers Prev 2006; 15: 2473-6.
30. Donovan JL, Chavin KD, Devane CL, et al. Green tea (Camellia sinensis) extract does not alter cytochrome p450 3A4 or 2D6 activity in healthy volunteers. Drug Metab Dispos 2004; 32: 906-8.
31. Chen C, Lin J, Smolarek T, Tremaine L. P-glycoprotein has differential effects on the disposition of statin acid and lactone forms in mdr1a/b knockout and wild-type mice. Drug Metab Dispos 2007; 35: 1725-9.
32. Holtzman CW, Wiggins BS, Spinler SA. Role of P-glycoprotein in statin drug interactions. Pharmacotherapy 2006; 26:1601-7.
33. Jodoin J, Demeule M, Beliveau R. Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols. Biochim Biophys Acta 2002; 1542: 149-59.
34. Qian F, Wei D, Zhang Q, Yang S. Modulation of P-glycoprotein function and reversal of multidrug resistance by (-)-epigallocatechin gallate in human cancer cells. Biomed Pharmacother 2005; 59: 64-9.
35. Choi JS, Burm JP. Effects of oral epigallocatechin gallate on the pharmacokinetics of nicardipine in rats. Arch Pharm Res 2009; 32: 1721-5.
36. Li C, Choi JS. Effects of epigallocatechin gallate on the bioavailability and pharmacokinetics of diltiazem in rats. Pharmazie 2008; 63: 815-8.
37. Chung JH, Choi DH, Choi JS. Effects of oral epigallocatechin gallate on the oral pharmacokinetics of verapamil in rats. Biopharm Drug Dispos 2009; 30: 90-3.
38. Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statininduced myopathy-a genomewide study. N Engl J Med 2008; 359: 789-99.
39. Ulvestad M, Skottheim IB, Jakobsen GS, et al. Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects. Clin Pharmacol Ther 2013; 93: 275-82.
40. Wilke RA, Ramsey LB, Johnson SG, et al. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther 2012; 92:112-7.
41. Roth M, Timmermann BN, Hagenbuch B. Interactions of green tea catechins with organic anion-transporting polypeptides. Drug Metab Dispos 2011; 39: 920-6.
42. Billecke S, Draganov D, Counsell R, et al. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos 2000; 28: 1335-42.
43. Riedmaier S, Klein K, Winter S, Hofmann U, Schwab M, Zanger UM. Paraoxonase (PON1 and PON3) Polymorphisms: Impact on Liver Expression and Atorvastatin-Lactone Hydrolysis. Front Pharmacol 2011; 2: 41.
44. Ginsberg G, Neafsey P, Hattis D, Guyton KZ, Johns DO, Sonawane B. Genetic polymorphism in paraoxonase 1 (PON1): Population distribution of PON1 activity. J Toxicol Environ Health B Crit Rev 2009; 12: 473-507.
45. Costa LG, Giordano G, Furlong CE. Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on. Biochem Pharmacol 2011; 81: 337-44.
46. Hsu SP, Wu MS, Yang CC, et al. Chronic green tea extract supplementation reduces hemodialysis-enhanced production of hydrogen peroxide and hypochlorous acid, atherosclerotic factors, and proinflammatory cytokines. Am J Clin Nutr 2007; 86: 1539-47.
47. Misaka S, Yatabe J, Muller F, et al. Green tea ingestion greatly reduces plasma concentrations of nadolol in healthy subjects. Clin Pharmacol Ther 2014; 95: 432-8.
48. Terao T, Hisanaga E, Sai Y, Tamai I, Tsuji A. Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J Pharm Pharmacol 1996; 48: 1083-9.
49. Miyazaki N, Misaka S, Ogata H, Fukushima T, Kimura J. Effects of itraconazole, dexamethasone and naringin on the pharmacokinetics of nadolol in rats. Drug Metab Pharmacokinet 2013; 28: 356-61.
50. Kato Y, Miyazaki T, Kano T, Sugiura T, Kubo Y, Tsuji A. Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol. J Pharm Sci 2009; 98: 2529-39.
51. Misaka S, Miyazaki N, Fukushima T, Yamada S, Kimura J. Effects of green tea extract and (-)-epigallocatechin-3-gallate on pharmacokinetics of nadolol in rats. Phytomedicine 2013; 20: 1247-50.